Regulus Therapeutics Inc (NASDAQ:RGLS) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 647,300 shares, an increase of 50.4% from the June 30th total of 430,500 shares. Based on an average daily trading volume, of 201,300 shares, the short-interest ratio is currently 3.2 days. Currently, 11.0% of the shares of the company are sold short.
RGLS has been the topic of several recent research reports. ValuEngine upgraded Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Wedbush restated a “hold” rating and issued a $1.00 price objective on shares of Regulus Therapeutics in a research report on Thursday, May 16th. Finally, Zacks Investment Research lowered Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Five equities research analysts have rated the stock with a hold rating, Regulus Therapeutics has a consensus rating of “Hold” and an average price target of $1.25.
In related news, insider Joseph P. Hagan sold 39,352 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $1.22, for a total value of $48,009.44. Following the sale, the insider now owns 307,519 shares in the company, valued at $375,173.18. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders sold 66,979 shares of company stock worth $85,896. 10.70% of the stock is owned by insiders.
Shares of NASDAQ:RGLS traded up $0.02 during midday trading on Monday, reaching $0.58. 78,800 shares of the company’s stock traded hands, compared to its average volume of 230,672. Regulus Therapeutics has a 1 year low of $0.50 and a 1 year high of $4.08. The stock has a market cap of $12.21 million, a P/E ratio of -0.10 and a beta of 1.90. The company has a fifty day simple moving average of $1.01.
Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.24. Regulus Therapeutics had a negative return on equity of 186,717.70% and a negative net margin of 396.84%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $2.50 million. Research analysts anticipate that Regulus Therapeutics will post -2.13 earnings per share for the current year.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Further Reading: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.